drugset / Trial / NCT01304784
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
Timeline
- Start
- 2011-01
- Primary completion
- 2014-04
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MM-111 | Unknown | — | — |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Background | Docetaxel | Small molecule | — | Intravenous |
| Background | Lapatinib | Small molecule | 1000 mg | Oral |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Background | Trastuzumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Background | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |